title: Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer.
abstract: BACKGROUND
  Evidence is increasing that elevated systemic inflammation is associated with poor survival in patients with oesophageal carcinoma. However, it is not yet established if any specific component of systemic inflammatory response is a better predictor of cancer survival. The aim of the present study was to compare the predictive value of selected markers of systemic inflammation in patients who undergo surgical resection of oesophageal cancer.
  
  
  METHODS
  One hundred twelve patients who underwent potentially curative resection for oesophageal carcinoma, including type I and type II tumours of the gastro-oesophageal junction (Siewert and Stein in Dis Esophagus 9:173-182, 1996), between 1996 and 2008 were included in the study. Patients had laboratory measurement of white cells, neutrophils, lymphocytes, platelet counts, albumin, and C-reactive protein. Glasgow Prognostic Score (mGPS), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and metastatic lymph node ratio (LNR) were calculated.
  
  
  RESULTS
  On multivariate analysis, only the LNR (HR 2.87, 95% CI 1.99-4.15, p < 0.001) and the mGPS (HR 4.31, 95% CI 2.20-8.45, p < 0.001) were independently associated with cancer-specific survival in oesophageal cancer. An elevated mGPS was associated with high white cell count (p < 0.05) and poorer survival (p = 0.001).
  
  
  CONCLUSIONS
  The present study indicates that the mGPS, an acute-phase protein-based prognostic score, better predicts cancer survival compared with the cellular components of systemic inflammation in patients with oesophageal carcinoma.
authors.affiliation: Academic Unit of Surgery, School of Medicine, University of Glasgow, Wolfson Medical School Bldg, University Ave, Glasgow, G12 8QQ, Scotland, UK. sdutta09@gmail.com
authors.forename: Sumanta
authors.initials: S
authors.lastname: Dutta
authors.forename: Andrew B C
authors.initials: AB
authors.lastname: Crumley
authors.forename: Grant M
authors.initials: GM
authors.lastname: Fullarton
authors.forename: Paul G
authors.initials: PG
authors.lastname: Horgan
authors.forename: Donald C
authors.initials: DC
authors.lastname: McMillan
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000276:immunology / Q000473:pathology / Q000601:surgery; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007958:Leukocyte Count; D008207:Lymphatic Metastasis / Q000473:pathology; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009504:Neutrophils / Q000276:immunology*; D010976:Platelet Count; D011237:Predictive Value of Tests; D011379:Prognosis; D012709:Serum Albumin / Q000032:analysis; D015996:Survival Rate
chemical_list: D018836:Inflammation Mediators; D012709:Serum Albumin; D002097:C-Reactive Protein